Kaisheng (Taiyuan) Biomaterials Co., Ltd. is a wholly owned subsidiary of Kaisheng Biotechnology Co., Ltd. (A-share code: 688065), established in Shanxi Province. It is positioned as a research and large-scale production base for bio-based new materials, falling within the interdisciplinary domain of “biomanufacturing” and “advanced functional materials” under China’s national strategic emerging industries, and is currently in an accelerated industrialization phase. The company’s core business encompasses research, pilot-scale testing, and industrial-scale production of long-chain dicarboxylic acids, bio-based pentamethylenediamine (PMDA), and bio-based polyamides (e.g., PA5X series). Its technological route starts from renewable carbon sources such as glucose, converts glucose into PMDA via microbial fermentation, and then condenses PMDA with long-chain dicarboxylic acids to produce bio-based polyamides whose performance matches that of petroleum-based nylons (e.g., PA66, PA610); these products feature low density, high heat resistance, good flame retardancy, and partial biodegradability. The company inherits Kaisheng Biotechnology’s globally leading synthetic biology platform and possesses high-efficiency, targeted microbial strain evolution capabilities based on microbial metabolic reprogramming. Related technologies have been granted dozens of Chinese invention patents (e.g., ZL201410792321.2, ZL201710220123.9, etc.), covering key processes for the biological production of PMDA and polymerization of high-molecular-weight compounds, achieving full-chain autonomy and control—from construction of genetically engineered strains, optimization of fermentation processes, separation and purification, to polymer modification. The company has obtained ISO 9001 Quality Management System certification; its production facilities comply with the requirements of the Biosecurity Law, the Good Manufacturing Practice for Pharmaceutical Products (applicable when producing pharmaceutical-grade intermediates), and the Discharge Permit Management Regulations. The Taiyuan site serves as the core implementation platform for Kaisheng Biotechnology’s “Full-Chain Bio-based Polyamide Industrial Project” and has been included in the Key Supported Projects list of the “Shanxi Province 14th Five-Year Plan for Emerging Industries and New Drivers of Growth.” It has also received funding support from the National Development and Reform Commission’s Special Fund for Industrial Foundation Reconstruction and High-Quality Development of the Manufacturing Industry. In 2022, the pilot production line was commissioned; in 2023, a demonstration facility with an annual capacity of 10,000 metric tons achieved stable operation, and its products passed certification by multiple downstream fiber and engineering plastic enterprises. In 2024, the company participated in formulating the group standard “Bio-based Polyamide Resin” (T/CBDA 112–2024). Currently, the company primarily serves domestic customers in sectors including chemical fibers, automotive lightweight components, and electronic/electrical structural parts, with collaboration directions encompassing joint development of bio-based materials, customized polymer supply, technical validation, and industrialization cooperation.